--- schema_version: "secwatch.filing_event.v1" accession: "0001610618-24-000050" form_type: "8-K" ticker: null cik: "0001610618" company_name: "Cidara Therapeutics, Inc." filed_at: "2024-04-24T23:59:59+00:00" generated_at: "2026-06-03T09:38:44.027399+00:00" event_type: "m_and_a" sentiment: "neutral" materiality_score: 0.85 calibrated_materiality_score: 0.85 confidence: "high" source: SEC EDGAR --- # Cidara sells rezafungin assets to NAPP/Mundipharma; debt forgiveness and milestone payment ## Summary - Sold all rezafungin acetate assets to NAPP Pharmaceutical Group Ltd, effective April 24, 2024. - Mundipharma forgave $11.145M development milestone advance due Dec 31, 2024, subject to conditions. - Received $2.786M milestone from Mundipharma for UK approval of rezafungin for invasive candidiasis. - Cidara agrees to 7-year non-compete for echinocandin antifungal products; exceptions if acquired. - Melinta license amended and novated to NAPP; Cidara provides transition services for 45-75 days. ## SEC filing metadata - accession: 0001610618-24-000050 - form_type: 8-K - cik: 0001610618 - company_name: Cidara Therapeutics, Inc. - filed_at: 2024-04-24T23:59:59+00:00 - event_type: m_and_a - sentiment: neutral - materiality_score: 0.85 - calibrated_materiality_score: 0.85 - confidence: high - sec_items: 1.01, 1.02, 2.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1610618/000161061824000050/0001610618-24-000050-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610618/000161061824000050/cdtx-20240423.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001610618-24-000050 - JSON: https://secwatch.observer/filing/0001610618-24-000050.json - Plain text: https://secwatch.observer/filing/0001610618-24-000050.txt ## Key facts - M&A Transactions Cidara Therapeutics, Inc. completed a disposition involving NAPP Pharmaceutical Group Limited (closed 2024-04-24). - Action: disposition - Counterparty: NAPP Pharmaceutical Group Limited - Closing: 2024-04-24 source text: the Company sold to NAPP, effective as of April 24, 2024, all of the Company’s rezafungin acetate assets evidence_url: https://www.sec.gov/Archives/edgar/data/1610618/000161061824000050/0001610618-24-000050-index.htm - Material Agreements Cidara Therapeutics, Inc. entered into Assignment and Novation Agreement with NAPP Pharmaceutical Group Limited and Mundipharma Medical Company valued at Transfer of Mundipharma Collaboration Agreement and Commercial Supply Agreement from Company to NAPP (effective 2024-04-24). - Action: entry - Agreement: collaboration - Counterparty: NAPP Pharmaceutical Group Limited and Mundipharma Medical Company - Value: Transfer of Mundipharma Collaboration Agreement and Commercial Supply Agreement from Company to NAPP - Effective: 2024-04-24 source text: The Company, NAPP and Mundipharma also entered into an Assignment and Novation Agreement to transfer the Mundipharma Collaboration Agreement and Commercial Supply Agreement from the Company to NAPP (the "Novation Agreement"). evidence_url: https://www.sec.gov/Archives/edgar/data/1610618/000161061824000050/0001610618-24-000050-index.htm - Material Agreements Cidara Therapeutics, Inc. terminated Asset Purchase Agreement-related termination with NAPP Pharmaceutical Group Limited valued at Termination of certain material definitive agreements in connection with asset sale; see Item 1.01 (effective 2024-04-24). - Action: termination - Agreement: asset purchase - Counterparty: NAPP Pharmaceutical Group Limited - Value: Termination of certain material definitive agreements in connection with asset sale; see Item 1.01 - Effective: 2024-04-24 source text: Item 1.02 Termination of a Material Definitive Agreement. See Item 1.01 above, which is incorporated by reference into this Item 1.02. evidence_url: https://www.sec.gov/Archives/edgar/data/1610618/000161061824000050/0001610618-24-000050-index.htm - Material Agreements Cidara Therapeutics, Inc. entered into Asset Purchase Agreement with NAPP Pharmaceutical Group Limited valued at Assumption of liabilities including costs of ReSPECT Phase 3 and ReSTORE Phase 3 clinical trials; fo (effective 2024-04-24). - Action: entry - Agreement: asset purchase - Counterparty: NAPP Pharmaceutical Group Limited - Value: Assumption of liabilities including costs of ReSPECT Phase 3 and ReSTORE Phase 3 clinical trials; fo - Effective: 2024-04-24 source text: On April 24, 2024, the Company and NAPP Pharmaceutical Group Limited, a company organized under the laws of England ("NAPP"), and an affiliate of Mundipharma Medical Company ("Mundipharma"), entered into an Asset Purchase Agreement (the "Purchase Agreement") pursuant to which the Company sold to NAPP, effective as of April 24, 2024, all of the Company's rezafungin acetate assets, including all of the Company's right to receive future milestones and royalties under the License Agreement, dated July 26, 2022 between the Company and Melinta Therapeutics, LLC, as amended, (the "Melinta License Agreement") and the License and Collaboration Agreement dated September 3, 2019 between the Company and Mundipharma, as amended, (the "Mundipharma Collaboration Agreement"), all rezafungin intellectual property rights, including patents and know-how, all product data, regulatory approvals and documentation, rezafungin and comparator inventory, specified prepaid assets and specified contracts, in exch evidence_url: https://www.sec.gov/Archives/edgar/data/1610618/000161061824000050/0001610618-24-000050-index.htm - Material Agreements Cidara Therapeutics, Inc. amended Melinta License Agreement with Melinta Therapeutics, LLC valued at Modified regulatory milestones payable upon receipt of marketing approval of rezafungin acetate for (effective 2024-04-23). - Action: amendment - Agreement: license - Counterparty: Melinta Therapeutics, LLC - Value: Modified regulatory milestones payable upon receipt of marketing approval of rezafungin acetate for - Effective: 2024-04-23 source text: In connection with the Purchase Agreement and as a condition to entering into the Purchase Agreement, the Company entered into an amendment, dated April 23, 2024, to the Melinta License Agreement (the "Melinta License Amendment") that, among other changes, modified the regulatory milestones payable upon receipt of marketing approval of the current rezafungin acetate product for an Additional Indication (as defined in the Melinta License Agreement). evidence_url: https://www.sec.gov/Archives/edgar/data/1610618/000161061824000050/0001610618-24-000050-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.